Combination therapy via oral co-administration of insulin- and exendin-4-loaded nanoparticles to treat type 2 diabetic rats undergoing OGTT

Er-Tuan Chuang, Giang Thi Ha Nguyen, Fang Yi Su, Kun Ju Lin, Chiung Tong Chen, Fwu Long Mi, Tzu Chen Yen, Jyuhn Huarng Juang, Hsing Wen Sung

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Current insulin therapy via subcutaneous administration can lead to occasional hypoglycemia and peripheral hyperinsulinemia, due to its nonphysiological route. This study evaluates the feasibility of using bovine insulin and exendin-4 in a form of combination therapy, as orally delivered by nanoparticles composed of chitosan and poly(γ-glutamic acid) (CS/γPGA NPs), to control blood glucose levels in rats with type 2 diabetes mellitus (T2DM) undergoing the oral glucose tolerance test. Experimental results indicate that CS/γPGA NPs could enhance the intestinal paracellular permeation; consequently, the exogenous bovine insulin and exendin-4 could be delivered into the liver and pancreas, where they could elicit their glucoregulatory activities. In response to the stimulus of exogenously delivered bovine insulin and the endogenously secreted rat insulin stimulated by the ingested exendin-4, significant glucose utilizations were found in the cardiac and skeletal muscles, resulting in the glucose-lowering effect. Owing to its synergic stimulation effects, the hypoglycemic effect of oral ingestion of NPs containing bovine insulin and exendin-4 was significantly greater than that of the group solely treated with insulin NPs. Above results demonstrate that oral combination therapy with bovine insulin and exendin-4 improves the modulation of blood glucose levels in T2DM rats, making it highly promising for treating those T2DM patients not adequately controlled by the current insulin therapy.

Original languageEnglish
Pages (from-to)7994-8001
Number of pages8
JournalBiomaterials
Volume34
Issue number32
DOIs
Publication statusPublished - Oct 2013

Fingerprint

Insulin
Glucose Tolerance Test
Nanoparticles
Oral Administration
Rats
Glucose
Medical problems
Type 2 Diabetes Mellitus
Prostaglandins A
Therapeutics
Blood Glucose
Blood
exenatide
Chitosan
Hyperinsulinism
Feasibility Studies
Hypoglycemia
Hypoglycemic Agents
Permeation
Liver

Keywords

  • Glucoregulatory activity
  • Glucose utilization
  • Hyperinsulinemia
  • Postprandial hyperglycemia
  • Translational medicine

ASJC Scopus subject areas

  • Biomaterials
  • Bioengineering
  • Ceramics and Composites
  • Mechanics of Materials
  • Biophysics

Cite this

Combination therapy via oral co-administration of insulin- and exendin-4-loaded nanoparticles to treat type 2 diabetic rats undergoing OGTT. / Chuang, Er-Tuan; Nguyen, Giang Thi Ha; Su, Fang Yi; Lin, Kun Ju; Chen, Chiung Tong; Mi, Fwu Long; Yen, Tzu Chen; Juang, Jyuhn Huarng; Sung, Hsing Wen.

In: Biomaterials, Vol. 34, No. 32, 10.2013, p. 7994-8001.

Research output: Contribution to journalArticle

Chuang, Er-Tuan ; Nguyen, Giang Thi Ha ; Su, Fang Yi ; Lin, Kun Ju ; Chen, Chiung Tong ; Mi, Fwu Long ; Yen, Tzu Chen ; Juang, Jyuhn Huarng ; Sung, Hsing Wen. / Combination therapy via oral co-administration of insulin- and exendin-4-loaded nanoparticles to treat type 2 diabetic rats undergoing OGTT. In: Biomaterials. 2013 ; Vol. 34, No. 32. pp. 7994-8001.
@article{f99101132c694bf88390f391f1dd092f,
title = "Combination therapy via oral co-administration of insulin- and exendin-4-loaded nanoparticles to treat type 2 diabetic rats undergoing OGTT",
abstract = "Current insulin therapy via subcutaneous administration can lead to occasional hypoglycemia and peripheral hyperinsulinemia, due to its nonphysiological route. This study evaluates the feasibility of using bovine insulin and exendin-4 in a form of combination therapy, as orally delivered by nanoparticles composed of chitosan and poly(γ-glutamic acid) (CS/γPGA NPs), to control blood glucose levels in rats with type 2 diabetes mellitus (T2DM) undergoing the oral glucose tolerance test. Experimental results indicate that CS/γPGA NPs could enhance the intestinal paracellular permeation; consequently, the exogenous bovine insulin and exendin-4 could be delivered into the liver and pancreas, where they could elicit their glucoregulatory activities. In response to the stimulus of exogenously delivered bovine insulin and the endogenously secreted rat insulin stimulated by the ingested exendin-4, significant glucose utilizations were found in the cardiac and skeletal muscles, resulting in the glucose-lowering effect. Owing to its synergic stimulation effects, the hypoglycemic effect of oral ingestion of NPs containing bovine insulin and exendin-4 was significantly greater than that of the group solely treated with insulin NPs. Above results demonstrate that oral combination therapy with bovine insulin and exendin-4 improves the modulation of blood glucose levels in T2DM rats, making it highly promising for treating those T2DM patients not adequately controlled by the current insulin therapy.",
keywords = "Glucoregulatory activity, Glucose utilization, Hyperinsulinemia, Postprandial hyperglycemia, Translational medicine",
author = "Er-Tuan Chuang and Nguyen, {Giang Thi Ha} and Su, {Fang Yi} and Lin, {Kun Ju} and Chen, {Chiung Tong} and Mi, {Fwu Long} and Yen, {Tzu Chen} and Juang, {Jyuhn Huarng} and Sung, {Hsing Wen}",
year = "2013",
month = "10",
doi = "10.1016/j.biomaterials.2013.07.021",
language = "English",
volume = "34",
pages = "7994--8001",
journal = "Biomaterials",
issn = "0142-9612",
publisher = "Elsevier Science Ltd",
number = "32",

}

TY - JOUR

T1 - Combination therapy via oral co-administration of insulin- and exendin-4-loaded nanoparticles to treat type 2 diabetic rats undergoing OGTT

AU - Chuang, Er-Tuan

AU - Nguyen, Giang Thi Ha

AU - Su, Fang Yi

AU - Lin, Kun Ju

AU - Chen, Chiung Tong

AU - Mi, Fwu Long

AU - Yen, Tzu Chen

AU - Juang, Jyuhn Huarng

AU - Sung, Hsing Wen

PY - 2013/10

Y1 - 2013/10

N2 - Current insulin therapy via subcutaneous administration can lead to occasional hypoglycemia and peripheral hyperinsulinemia, due to its nonphysiological route. This study evaluates the feasibility of using bovine insulin and exendin-4 in a form of combination therapy, as orally delivered by nanoparticles composed of chitosan and poly(γ-glutamic acid) (CS/γPGA NPs), to control blood glucose levels in rats with type 2 diabetes mellitus (T2DM) undergoing the oral glucose tolerance test. Experimental results indicate that CS/γPGA NPs could enhance the intestinal paracellular permeation; consequently, the exogenous bovine insulin and exendin-4 could be delivered into the liver and pancreas, where they could elicit their glucoregulatory activities. In response to the stimulus of exogenously delivered bovine insulin and the endogenously secreted rat insulin stimulated by the ingested exendin-4, significant glucose utilizations were found in the cardiac and skeletal muscles, resulting in the glucose-lowering effect. Owing to its synergic stimulation effects, the hypoglycemic effect of oral ingestion of NPs containing bovine insulin and exendin-4 was significantly greater than that of the group solely treated with insulin NPs. Above results demonstrate that oral combination therapy with bovine insulin and exendin-4 improves the modulation of blood glucose levels in T2DM rats, making it highly promising for treating those T2DM patients not adequately controlled by the current insulin therapy.

AB - Current insulin therapy via subcutaneous administration can lead to occasional hypoglycemia and peripheral hyperinsulinemia, due to its nonphysiological route. This study evaluates the feasibility of using bovine insulin and exendin-4 in a form of combination therapy, as orally delivered by nanoparticles composed of chitosan and poly(γ-glutamic acid) (CS/γPGA NPs), to control blood glucose levels in rats with type 2 diabetes mellitus (T2DM) undergoing the oral glucose tolerance test. Experimental results indicate that CS/γPGA NPs could enhance the intestinal paracellular permeation; consequently, the exogenous bovine insulin and exendin-4 could be delivered into the liver and pancreas, where they could elicit their glucoregulatory activities. In response to the stimulus of exogenously delivered bovine insulin and the endogenously secreted rat insulin stimulated by the ingested exendin-4, significant glucose utilizations were found in the cardiac and skeletal muscles, resulting in the glucose-lowering effect. Owing to its synergic stimulation effects, the hypoglycemic effect of oral ingestion of NPs containing bovine insulin and exendin-4 was significantly greater than that of the group solely treated with insulin NPs. Above results demonstrate that oral combination therapy with bovine insulin and exendin-4 improves the modulation of blood glucose levels in T2DM rats, making it highly promising for treating those T2DM patients not adequately controlled by the current insulin therapy.

KW - Glucoregulatory activity

KW - Glucose utilization

KW - Hyperinsulinemia

KW - Postprandial hyperglycemia

KW - Translational medicine

UR - http://www.scopus.com/inward/record.url?scp=84881029137&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84881029137&partnerID=8YFLogxK

U2 - 10.1016/j.biomaterials.2013.07.021

DO - 10.1016/j.biomaterials.2013.07.021

M3 - Article

C2 - 23891516

AN - SCOPUS:84881029137

VL - 34

SP - 7994

EP - 8001

JO - Biomaterials

JF - Biomaterials

SN - 0142-9612

IS - 32

ER -